ArticleNPJ vaccines2025
Immunogenicity, immune persistence, and safety of japanese encephalitis vaccine schedules among adults in Ningxia, China.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Japanese Encephalitis Virus and Host Innate Immunity: Insights Into TLR Signaling, PRR Crosstalk, and Viral Immune Evasion.Cell biochemistry and function · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Live attenuated and vero-cell-inactivated Japanese Encephalitis vaccines (LJEV, IJEV) have been in common use in young children in China since 1989 and 2004, associated with large reductions in Japanese encephalitis (JE) incidence. In 2013, northern China reported JE outbreaks among adults born before JE vaccine availability, a trend that worsened in 2017-2018. We conducted an open-label, randomized, controlled trial (ChiCTR2500103235) to assess the immunogenicity, immune persistence, and safety of three JE vaccine schedules in 40-69-year-olds to provide evidence for adult targeted JE immunization efforts. Outcomes were seroconversion proportions and seropositive prevalences; adverse events were monitored. The vaccines were immunogenic with no significant difference between vaccination groups. Seropositivity remained above 80% at one year post-vaccination. No serious adverse events occurred. All three schedules had good, persistent immunogenicity and favorable safety profiles in 40-69-year-old adults, providing evidence supporting vaccinating adults in response to the emergence of adult JE in northern China.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.